Improved design and intranasal delivery of an M2e-based human influenza A vaccine
- PMID: 16814430
- DOI: 10.1016/j.vaccine.2006.05.082
Improved design and intranasal delivery of an M2e-based human influenza A vaccine
Abstract
M2 is the third integral membrane protein of influenza A. M2e, the extracellular, 23 amino acid residues of M2, has been remarkably conserved in all human influenza A strains. This prompted us to evaluate the use of M2e as a potential broad-spectrum immunogen in a mouse model for influenza infection. Genetic fusion of the M2e and hepatitis B virus core (HBc) coding sequences allowed us to obtain highly immunogenic virus-like particles. This M2e-HBc vaccine induced complete protection in mice against a lethal influenza challenge. Protective immunity was obtained regardless of the position of M2e in the M2e-HBc chimera at the amino-terminus or inserted in the immuno-dominant loop of the HBc protein. Increasing the copy number of M2e inserted at the N-terminus from one to three per monomer (240-720 per particle) significantly enhanced the immune response and reduced the number of vaccinations required for complete protection against a lethal challenge with influenza A virus. A series of M2e-HBc constructs was subsequently combined with CTA1-DD, a recombinant cholera toxin A1 derived mucosal adjuvant, to test its efficacy as an intranasally delivered vaccine. All hybrid VLPs tested with CTA1-DD completely protected mice from a potentially lethal infection and, in addition, significantly reduced morbidity. Overall, increased resistance to influenza challenge in the mice correlated with an enhanced Th1-type M2e-specific antibody response induced by vaccination. These results show that M2e is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
Similar articles
-
The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.Vaccine. 2006 Jan 30;24(5):544-51. doi: 10.1016/j.vaccine.2005.08.061. Epub 2005 Aug 31. Vaccine. 2006. PMID: 16169634
-
Universal influenza A vaccine: optimization of M2-based constructs.Virology. 2005 Jun 20;337(1):149-61. doi: 10.1016/j.virol.2005.04.004. Virology. 2005. PMID: 15914228
-
A "universal" human influenza A vaccine.Virus Res. 2004 Jul;103(1-2):173-6. doi: 10.1016/j.virusres.2004.02.030. Virus Res. 2004. PMID: 15163506 Review.
-
CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10. Vaccine. 2008. PMID: 18243429
-
M2e-based universal influenza A vaccine.Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Vaccine. 2009. PMID: 19840661 Review.
Cited by
-
Isolation and mutation trend analysis of influenza A virus subtype H9N2 in Egypt.Virol J. 2012 Aug 27;9:173. doi: 10.1186/1743-422X-9-173. Virol J. 2012. PMID: 22925485 Free PMC article.
-
Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype.Vaccine. 2010 Sep 24;28(41):6704-13. doi: 10.1016/j.vaccine.2010.07.083. Epub 2010 Aug 5. Vaccine. 2010. PMID: 20691653 Free PMC article.
-
The Quest for a Truly Universal Influenza Vaccine.Front Cell Infect Microbiol. 2019 Oct 10;9:344. doi: 10.3389/fcimb.2019.00344. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31649895 Free PMC article. Review.
-
Escherichia coli-derived virus-like particles in vaccine development.NPJ Vaccines. 2017 Feb 9;2:3. doi: 10.1038/s41541-017-0006-8. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263864 Free PMC article.
-
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.J Nanobiotechnology. 2021 Feb 25;19(1):59. doi: 10.1186/s12951-021-00806-7. J Nanobiotechnology. 2021. PMID: 33632278 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
